The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

BJU International

Volumn 93, Issue 6, 2004, Pages 720-724

  Bangma, C H ^a   Wildhagen, M F ^a   Yurdakul, G ^a   Schroder F H ^a   Blijenberg, B G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Grading; Isoforms; Kallikrein; ProPSA; Prostate cancer; PSA

Indexed keywords

KALLIKREIN; KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR BIOPSY;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TISSUE KALLIKREINS;

EID: 1942478485     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04733.x     Document Type: Article

References (20)

1. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797-802.
2. Nurmikko P, Vaisanen V, Piironen T, Lindgren S, Lilja H, Pettersson K, Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000; 46: 1610-8
3. Mikolajczyk SD, Marker KM, Millar LS et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001; 61: 6958-63
4. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001; 61: 957-62
5. Darson MF, Pacelli A, Roche P et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997; 49: 857-62
6. Kumar A, Mikolajczyk SD, Hill TM, Millar LS, Saedi MS. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate 2000; 44: 248-54
7. Recker F, Kwiatkowski MK, Piironen T et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 2000; 55: 481-5
8. Haese A, Graefen M, Steuber T et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001; 49: 101-9
9. Schroder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-23
10. Finlay JA, Day JR, Evans CL et al. Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 2001; 47: 1218-24
11. Hösel W, Peter J, Hübel-Parajsz C. Development and evaluation of an ELISA for the measurement of proPSA forms in sera. Anticancer Res 2002; 22: 529
12. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology 2000; 55: 694-9
13. Sokoll U, Chan DW, Mikolajczyk SD et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2003; 61: 274-6
14. Paus E, Nilsson O, Bormer OP, Fossa SD, Otnes B, Skovlund E. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. Urol 1998; 159: 1599-605
15. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schroder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997; 157: 2191-6
16. Brawer MK, Cheli CD, Neaman IE et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80
17. Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-73
18. Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schroder FH. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate 2001; 47: 252-61
19. Narain V, Bianco FJ Jr, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival? Prostate 2001; 49: 185-90
20. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 1997; 157: 544-7